Sanofi has permanently halted its Phase 3 RSV vaccine trial in infants and toddlers following a serious adverse event involving an infant death, which was later linked to an underlying health condition that should have excluded the child from the study. The decision has drawn heightened regulatory attention, including Freedom of Information Act requests to the FDA, and raises concerns about RSV vaccine safety in very young children. This move affects Sanofi's vaccine R&D pipeline and has scientific and reputational implications in the pediatric vaccine market, potentially influencing investor views on its broader role in childhood infectious disease prevention.
Sanofi SAPermanent halt of Phase 3 RSV vaccine trial due to infant death and safety concerns.
Banco Santander S.A.